CG Oncology, Inc.
CGON
$20.64
$0.422.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -55.83% | -7.94% | -11.65% | -2.28% | -- |
| Total Depreciation and Amortization | -100.00% | 200.00% | 75.00% | 0.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 487.02% | 562.17% | 66.42% | -2.24% | -- |
| Change in Net Operating Assets | 43.92% | 13.14% | 135.80% | -424.91% | -- |
| Cash from Operations | -29.79% | 1.25% | 38.03% | -77.62% | -- |
| Capital Expenditure | -21,000.00% | 107.14% | -16.67% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.27% | 188.37% | 88.22% | -2,079.09% | -- |
| Cash from Investing | -65.93% | 188.34% | 88.22% | -2,079.17% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -5,114.29% | -- |
| Issuance of Common Stock | 10,209.83% | 2,714.29% | -99.98% | 155,018.32% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 98.91% | 4.89% | -- |
| Cash from Financing | 10,209.83% | 5,317.50% | -99.99% | 14,003.94% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,070.53% | 134.89% | -175.59% | 3,548.03% | -- |